Park Ha Biological Technology Co Ltd Dossier - Source-backed chat

Park Ha Biological Technology Co Ltd

BYAHNASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.62

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.27Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $1.8M

Enterprise Value −$1.8M

Shares Outstanding 795.5K diluted

Next Earnings Date28 Feb 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Park Ha Biological Technology Co., Ltd. (BYAH) is a micro-cap skincare and cosmetics company operating in China. While the company maintains an exceptionally high gross profit margin of 94.4% due to its direct-cost model and franchise structure, it suffered a massive net loss of $24.4 million in FY2025 driven by a surge in SG&A expenses to $25.5 million. The stock has experienced extreme volatility, including a 1-for-50 reverse stock split in February 2026 to regain Nasdaq compliance, and a massive short-term rally in June 2026 following the announcement of an AI-powered skincare partnership with Star Plus Action. Given the high execution risks, volatile earnings quality, and micro-cap liquidity constraints, a Hold recommendation is warranted until the financial impact of the new AI initiatives and overhead cost controls are demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The AI skincare initiatives fail to gain traction, and the partnership with Star Plus Action does not yield material financial benefits. Operating expenses remain unsustainably high, rapidly depleting the company's cash reserves. The company is forced to execute highly dilutive equity offerings under its $300 million shelf registration, and the stock faces renewed Nasdaq delisting pressures.

Base CaseCentral scenario

$1.5060%

The company stabilizes its operating expenses while slowly expanding its franchise network. The newly launched AI Nutritionist pilot and planned AI store managers with Star Plus Action help improve customer engagement and franchise efficiency, but do not immediately generate substantial new revenue streams. Revenue grows at a modest single-digit rate, and operating losses narrow as non-recurring SG&A expenses subside.

Bull CaseUpside scenario

$3.0025%

The strategic partnership with Star Plus Action scales rapidly, driving significant high-margin franchise fee growth and product sales. The AI-powered store managers and virtual skincare specialists successfully digitalize operations, leading to a sharp reduction in SG&A expenses and a return to profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

Extremely high gross profit margin of 94.4% in FY2025, reflecting strong pricing power and low direct product costs.
Strategic AI-powered skincare partnership with Star Plus Action, leveraging prominent celebrity IP and digital avatars to modernize the retail experience.
Conservative debt profile with zero long-term debt and a solid cash position relative to its small operating scale.

Key Investment Risks

Severe operating loss of $24.4 million in FY2025 due to a massive spike in SG&A expenses.
Extreme stock price volatility and history of compliance issues, requiring a 1-for-50 reverse stock split in early 2026.
High execution and commercialization risks associated with the unproven AI skincare and wellness ecosystem.

Thesis Invalidation Triggers

Failure to maintain Nasdaq minimum bid price compliance leading to delisting warnings.
Further material expansion of SG&A expenses without corresponding revenue growth, leading to rapid cash burn.
Termination or lack of progress in the strategic partnership with Star Plus Action.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.